CBMX : Summary for CombiMatrix Corporation - Yahoo Finance

U.S. Markets closed

CombiMatrix Corporation (CBMX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.40+0.30 (+7.32%)
At close: 4:00PM EST

4.36 -0.05 (-1.02%)
After hours: 7:57PM EST

People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close4.10
Bid4.35 x 1000
Ask4.45 x 100
Day's Range4.15 - 4.90
52 Week Range2.15 - 7.96
Avg. Volume294,362
Market Cap11M
PE Ratio (TTM)-0.85
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    CombiMatrix Corporation Reports 2016 Fourth Quarter and Full Year Financial and Operating Results

    Achieves record quarterly reproductive health revenues and test volume, across-the-board increases in average revenue per test, expanded gross margin, significantly narrowed operating loss and record cash ...

  • GlobeNewswire9 days ago

    CombiMatrix Corporation to Release 2016 Fourth Quarter and Full Year Financial Results on February 22, 2017

    IRVINE, Calif., Feb. 15, 2017-- CombiMatrix Corporation, a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces that it will ...

  • Zacks Small Cap Research14 days ago

    CBMX:Expect Record Revenue, Profit in 2017 On Strong Fundamentals

    Through the first nine months of 2016 CombiMatrix’s (CBMX) revenue is up 26%, gross margin is 800 basis points wider, operating loss is 28% lower and EBITDA loss is improved by almost 38% as compared to the same period in 2015.  As we have recently noted, we characterize the improved financial performance as ‘high quality’ and what reasonably could be expected to be replicable given that these are the products of CombiMatrix’s direct efforts and/or favorable changes in industry fundamentals. CBMX has been actively engaged in their fate by targeting geographic areas with favorable reimbursement, sponsoring or otherwise supporting evidence-based studies, communicating with payers and optimizing their product portfolio to include cash-pay products.  The company’s recent implementation of a new compensation model and other efficiency initiatives has resulted in a rapid and substantial shedding of expenses.  And favorable changes in payers’ coverage decisions, CBMX’s investments in billing and collections resources and their deft updates to their product portfolio have contributed to margin expansion and greatly improved cash collections.